NR2E3 and myeloid sarcoma: However, precisely due to the inhibition of RNR and immunosuppressive properties, deoxynucleoside derivatives, such as cladribine (chlorodeoxyadenosine, CdA), became disease-modifying therapies for MS (Giovannoni, 2017).